Compare ZKIN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | RNXT |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 79.4M |
| IPO Year | 2017 | 2021 |
| Metric | ZKIN | RNXT |
|---|---|---|
| Price | $1.70 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.13 |
| AVG Volume (30 Days) | 54.8K | ★ 551.1K |
| Earning Date | 08-21-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.00 | $0.70 |
| 52 Week High | $3.11 | $2.59 |
| Indicator | ZKIN | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 35.72 |
| Support Level | $1.30 | $0.83 |
| Resistance Level | $1.94 | $1.28 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 4.81 | 20.54 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.